A dual label oligonucleotide ligation assay for detection of the CYP2C19*1, CYP2C19*2, and CYP2C19*3 alleles involving time-resolved fluorometry

被引:11
|
作者
Bathum, L
Hansen, TS
Horder, M
Brosen, K
机构
[1] Odense Univ Hosp, Dept Clin Biochem, DK-5000 Odense C, Denmark
[2] Odense Univ, Dept Clin Pharmacol, DK-5230 Odense, Denmark
关键词
CYP2C19; genotyping; genetic polymorphism;
D O I
10.1097/00007691-199802000-00001
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
CYP2C19 (S-mephenytoin hydroxylase) is a polymorphically expressed enzyme. Currently, two defective alleles are known-CYP2C19*2 and CYP2C19*3. The authors have developed an oligonucleotide ligation assay to detect these two alleles. This assay combines the hybridization of one common, biotinylated capture probe and two allele-specific probes to the target DNA, with the ability of a DNA ligase to distinguish mismatched nucleotides. The probes are only ligated if they are base paired correctly to the target strand. The biotin is bound to streptavidin, and all DNA not covalently bound to the biotin-labeled capture probe, is removed in a washing procedure. The allele-specific probes are labeled with either europium or samarium, and their emission can be measured simultaneously. The ratio between the emission separates the genotypes. This method was applied on DNA from 19 whites and 21 Vietnamese living in Denmark. All genotypes determined by the assay were consistent with the results from restriction enzyme cleavage. There were 12 poor metabolizers; 10 homozygous CYP2C19*2/CYP2C19*2, one heterozygous CYP2C19*2/CYP2C19*3, and one heterozygous CYP2C19*1/CYP2C19*2. The authors conclude that this assay is well-suited for a high throughput of samples in a routine laboratory. The finding of an apparently heterozygous CYP2C19*1/CYP2C19*2 poor metabolizer, confirms that there are still unknown mutations in CYP2C19.
引用
收藏
页码:1 / 6
页数:6
相关论文
共 50 条
  • [21] Effects of CYP2C19 variants on the metabolism of tapentadol in vitro
    Xu, Ren-ai
    Fang, Ping
    Ye, Zhize
    Han, Mingming
    Cai, Jian-Ping
    Hu, Guo-Xin
    IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2022, 25 (05) : 659 - 663
  • [22] Allele and genotype frequency of CYP2C19 in a Tamilian population
    Adithan, C
    Gerard, N
    Vasu, S
    Rosemary, J
    Shashindran, CH
    Krishnamoorthy, R
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 (03) : 331 - 333
  • [23] Effects of genetic polymorphisms of CYP2C19 on the pharmacokinetics of zolpidem
    Ji-Yeong Byeon
    Young-Hoon Kim
    Se-Hyung Kim
    Choong-Min Lee
    Eui-Hyun Jung
    Won-Ki Chae
    Choon-Gon Jang
    Seok-Yong Lee
    Yun Jeong Lee
    Archives of Pharmacal Research, 2018, 41 : 861 - 866
  • [24] Effects of CYP2C19 Variants on Fluoxetine Metabolism in vitro
    Fang, Ping
    He, Jia-Yang
    Han, Ai-Xia
    Lan, Tian
    Dai, Da-Peng
    Cai, Jian-Ping
    Hu, Guo-Xin
    PHARMACOLOGY, 2017, 100 (1-2) : 91 - 97
  • [25] The impact of CYP2C19 genotype on phenoconversion by concomitant medication
    de Jong, Laura M.
    Boussallami, Soukayna
    Sanchez-Lopez, Elena
    Giera, Martin
    Tushuizen, Maarten E.
    Hoekstra, Menno
    Hawinkels, Lukas J. A. C.
    Rissmann, Robert
    Swen, Jesse J.
    Manson, Martijn L.
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [26] Frequency distribution of high risk alleles of CYP2C19, CYP2E1, CYP3A4 genes in Haryana population
    Gulati, Sachin
    Yadav, Anita
    Kumar, Neeraj
    Kanupriya
    Kumar, Gaurav
    Aggarwal, Neeraj
    Gupta, Ranjan
    ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY, 2014, 37 (03) : 1186 - 1193
  • [27] Genetic Polymorphisms and in Vitro Functional Characterization of CYP2C8, CYP2C9, and CYP2C19 Allelic Variants
    Hiratsuka, Masahiro
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2016, 39 (11) : 1748 - 1759
  • [28] Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism
    Shi, Hui-Yan
    Yan, Jin
    Zhu, Wen-Hui
    Yang, Guo-Ping
    Tan, Zhi-Rong
    Wu, Wei-Hua
    Zhou, Gan
    Chen, Xiao-Ping
    Ouyang, Dong-Sheng
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 66 (11) : 1131 - 1136
  • [29] CYP2C19 genetic polymorphism in Thai, Burmese and Karen populations
    Tassaneeyakul, Wichittra
    Mahatthanatrakul, Werawath
    Niwatananun, Kanokporn
    Na-Bangchang, Kesara
    Tawalee, Arporn
    Krikreangsak, Nathawut
    Cykleng, Utaiwan
    Tassaneeyakul, Wongwiwat
    DRUG METABOLISM AND PHARMACOKINETICS, 2006, 21 (04) : 286 - 290
  • [30] Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism
    Hui-Yan Shi
    Jin Yan
    Wen-Hui Zhu
    Guo-Ping Yang
    Zhi-Rong Tan
    Wei-Hua Wu
    Gan Zhou
    Xiao-Ping Chen
    Dong-Sheng Ouyang
    European Journal of Clinical Pharmacology, 2010, 66 : 1131 - 1136